Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

JPMORGAN HEALTHCARE LEADERS ETF

59.56
+0.08390.14%
Post-market: 59.47-0.0839-0.14%16:10 EDT
Volume:46
Turnover:3K
Market Cap:8.93M
PE:- -
High:59.56
Open:59.47
Low:59.56
Close:59.47
52wk High:64.69
52wk Low:53.59
Shares:150.00K
Float Shares:150.00K
Volume Ratio:0.55
T/O Rate:0.03%
Dividend:0.51
Dividend Rate:0.86%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Eli Lilly Price Target Maintained with a $1250.00/Share by TD Cowen

Dow Jones
·
Sep 22

Dow Falls 134 Points on Losses for Shares of Cisco, JPMorgan Chase

Dow Jones
·
Sep 22

Viking Therapeutics Stock Surges 35%. It Could Challenge Lilly and Novo's Obesity Empire

Dow Jones
·
Sep 22

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 22

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 22

Adagene Wins NMPA IND Clearance for Novel HER2xCD3 T-Cell Engager ADG138

TIPRANKS
·
Sep 22

Viking Therapeutics Stock Surges 36%. it Could Challenge Lilly and Novo's Obesity Empire.

Dow Jones
·
Sep 22

DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026

Reuters
·
Sep 22

J&J DePuy Synthes to Showcase Next-Generation Trauma Devices at Orthopaedic Trauma Association Annual Meeting

Reuters
·
Sep 22

Merck Gets FDA Label Update for WINREVAIR Based on HYPERION Trial

MT Newswires Live
·
Sep 22

Merck says FDA approves update for U.S. product label for Winrevair

TIPRANKS
·
Sep 22

U.S. FDA Approves Update to the Label for Winrevair to Include Data from the Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension

Reuters
·
Sep 22

Merck Says Phase 3 Hyperion Trial Shows Winrevair Cuts PAH Clinical Worsening Risk 76%

Reuters
·
Sep 22

AbbVie: EC approves Rinvoq to treat polyarticular juvenile idiopathic arthritis

TIPRANKS
·
Sep 22

Roche says Phase II obesity study met both primary endpoints

TIPRANKS
·
Sep 22

AbbVie Announces European Commission Approval of Rinvoq (Upadacitinib)

Reuters
·
Sep 22

AbbVie Says EU Approves Rinvoq for Children with Polyarticular Juvenile Idiopathic Arthritis

Reuters
·
Sep 22

Abbvie Announces European Commission Approval of Rinvoq® (Upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

THOMSON REUTERS
·
Sep 22

Abbvie - Rinvoq Approved in EU for Pjia in Patients Aged Two Years and Older

THOMSON REUTERS
·
Sep 22

Kolmar Biotech Finalizes Low-Risk Merger of Wholly Owned Unit MOD Materials

TIPRANKS
·
Sep 22
More